Gastroenterology
Volume 129, Issue 3 , Pages 807-818 , September 2005

A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn’s Disease

Presented in part at the American Gastroenterological Association Digestive Disease Week (Orlando, Florida, May 17–22, 2003), the American College of Gastroenterology 68th Annual Scientific Meeting (Baltimore, Maryland, October 10–15, 2003), and the United European Gastroenterology Week (Madrid, Spain, November 1–5, 2003).

  • Stefan Schreiber

      Affiliations

    • Hospital for General Internal Medicine, Christian-Albrechts University, Klinik für Allgemeine Innere Medizin, Kiel, Germany
    • Institute for Clinical Molecular Biology, Christian-Albrechts University, Klinik für Allgemeine Innere Medizin, Kiel, Germany
    • Corresponding Author InformationAddress requests for reprints to: Stefan Schreiber, MD, Christian-Albrechts University, Klinik für Allgemeine Innere Medizin, Schittenhelmstrasse 12, Kiel 24105, Germany.fax: (49) 431-597-1842
    • ,
  • Paul Rutgeerts

      Affiliations

    • University Hospital Leuven, Gastroenterology, Leuven, Belgium
    • ,
  • Richard N. Fedorak

      Affiliations

    • University of Alberta, Division of Gastroenterology, Edmonton, Alberta, Canada
    • ,
  • Munaa Khaliq–Kareemi

      Affiliations

    • Dalhousie University, Halifax, Nova Scotia, Canada
    • ,
  • Michael A. Kamm

      Affiliations

    • St Mark’s Hospital, London, United Kingdom
    • ,
  • Michel Boivin

      Affiliations

    • Hôpital St Luc, Montreal, Canada
    • ,
  • Charles N. Bernstein

      Affiliations

    • University of Manitoba, Winnipeg, Canada
    • ,
  • Michael Staun

      Affiliations

    • Department of Gastroenterology, Rigshospitalet, Copenhagen, Denmark
    • ,
  • Ole Østergaard Thomsen

      Affiliations

    • Department of Gastroenterology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
    • ,
  • Alison Innes

      Affiliations

    • UCB Research and Development, Slough, Berkshire, United Kingdom
    • ,
  • CDP870 Crohn’s Disease Study Group

Received 14 September 2004 ,Accepted 26 May 2005.

References 

  1. Murch SH , Lamkin VA , Savage MO , Walker-Smith JA , MacDonald TT . Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease . Gut . 1991;32:913–917
  2. Murch SH , Braegger CP , Walker-Smith JA , MacDonald TT . Localisation of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease . Gut . 1993;34:1705–1709
  3. Braegger CP , Nicholls S , Murch SH , Stephens S , MacDonald TT . Tumour necrosis factor alpha in stool as a marker of intestinal inflammation . Lancet . 1992;339:89–91
  4. Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease . Clin Exp Immunol . 1993;94:174–181
  5. van Deventer SJ . Tumour necrosis factor and Crohn’s disease . Gut . 1997;40:443–448
  6. Schreiber S, Nikolaus S, Hampe J, Hamling J, Koop I, Groessner B, et al. Tumour necrosis factor α and interleukin 1β in relapse of Crohn’s disease . Lancet . 1999;353:459–461
  7. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn’s disease . Lancet . 1997;349:521–524
  8. Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor alpha for Crohn’s disease . N Engl J Med . 1997;337:1029–1035
  9. Rutgeerts P, D’Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease . Gastroenterology . 1999;117:761–769
  10. Rutgeerts P , Lemmens L , Van Assche G , Noman M , Borghini-Fuhrer I , Goedkoop R . Treatment of active Crohn’s disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor) (results of a randomized, open-label, pilot study) . Aliment Pharmacol Ther . 2003;17:185–192
  11. Nikolaus S , Raedler A , Kühbacher T , Sfikas N , Fölsch UR , Schreiber S . Mechanisms in failure of infliximab for Crohn’s disease . Lancet . 2000;356:1475–1479
  12. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel S, et al. Maintenance infliximab for Crohn’s disease) (the ACCENT I randomised trial) . Lancet . 2002;359:1541–1549
  13. Hanauer SB , Sandborn WJ  Practice Parameters Committee of the American College of Gastroenterology . Management of Crohn’s disease in adults . Am J Gastroenterol . 2001;96:635–643
  14. Schreiber S, Campieri M, Colombel JF, van Deventer SJH, Feagan B, Fedorak R, et al. Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001–2003 . Int J Colorectal Dis . 2001;16:1–11
  15. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease . N Engl J Med . 1999;340:1398–1405
  16. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease . N Engl J Med . 2004;350:876–885
  17. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schweiterman WD, et al. Tuberculosis associated with infliximab, a tumour necrosis factor alpha-neutralizing agent . N Engl J Med . 2001;345:1098–1104
  18. Baert F, Noman M, Vermeire S, Van Assche G, D’Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease . N Engl J Med . 2003;348:601–608
  19. Farrell RJ , Alsahli M , Jeen YT , Falchuk KR , Peppercorn MA , Michetti P . Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease) (a randomized controlled trial) . Gastroenterology . 2003;124:917–924
  20. Sandborn WJ . Preventing antibodies to infliximab in patients with Crohn’s disease) (optimize not immunize) . Gastroenterology . 2003;124:1140–1145
  21. Keystone E, Choy EH, Kalden J, Klareskog L, Sany J, Smolen J, et al. CDP870, a novel, PEGylated, humanized TNF-α inhibitor is effective in treating the signs and symptoms of rheumatoid arthritis (RA) . 2001; Late-breaking Abstract No. LB-3 presented at the American College of Rheumatology, 65th Annual Scientific Meeting, San Francisco, CA (not included in the abstract proceedings)
  22. Choy EH, Hazleman B, Smith M, Moss K, Lisi L, Scott DG, et al. Efficacy of a novel humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis) (a phase II double-blinded, randomized, dose-escalating trial) . Rheumatology (Oxford) . 2002;41:1133–1137
  23. Best WR , Becktel JM , Singleton JW , Kern F . Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study . Gastroenterology . 1976;70:439–444
  24. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, et al. Quality of life) (a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease) . Gastroenterology . 1994;106:287–296
  25. Koch GG , Gansky SA . Statistical considerations for multiplicity in confirmatory protocols . Drug Inf J . 1996;30:523–533
  26. Fagan EA, Dyck RF, Maton PN, Hodgson HJ, Chadwick VS, Petrie A, et al. Serum levels of C-reactive protein in Crohn’s disease and ulcerative colitis . Eur J Clin Invest . 1982;12:351–359
  27. Poullis AP, Zar S, Sundaram KK, Moodie SJ, Risley P, Theodossi A, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders . Eur J Gastroenterol Hepatol . 2002;14:409–412
  28. Tromm A , Tromm CD , Huppe D , Schwegler U , Krieg M , May B . Evaluation of different laboratory tests and activity indices reflecting the inflammatory activity of Crohn’s disease . Scand J Gastroenterol . 1992;27:774–778
  29. Niederau C , Backmerhoff F , Schumacher B , Niederau C . Inflammatory mediators and acute phase proteins in patients with Crohn’s disease and ulcerative colitis . Hepatogastroenterology . 1997;44:90–107
  30. Brignola C , Campieri M , Bazzocchi G , Farrugia P , Tragnone A , Lanfranchi GA . A laboratory index for predicting relapse in asymptomatic patients with Crohn’s disease . Gastroenterology . 1986;91:1490–1494
  31. Rutgeerts P, Colombel J, Enns R, Feagan B, Hanauer S, Lawrance I, et al. Subanalyses from a phase 3 study on the evaluation of natalizumab in active Crohn’s disease therapy-1 (ENACT-1) . Gut . 2003;52(Suppl VI):A239
  32. Su C , Lichtenstein GR , Krok K , Brensinger C , Lewis JD . A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn’s disease . Gastroenterology . 2004;126:1257–1269
  33. Will M , Nikolaus S , Freitag S , Arpe N , Krawczak M , Schreiber S . Placebo response in the therapy of Crohn’s disease (a comprehensive analysis of primary data from 733 patients from 13 randomized, controlled trials) . 2005; Abstract No. 338 presented at Digestive Disease Week 2005, Chicago, IL
  34. van de Putte LBA, Atkins C, Malaise M, Sany J, Russell AS, van Riel PLCM, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed . Ann Rheum Dis . 2004;63:508–516

 Supported by Celltech R&D, Ltd. The German Federal Ministry for Education and Research Competence Network “Inflammatory Bowel Disease” provided additional support with the organization of the trial. S.S., P.R., and O.Ø.T. have served as paid consultants to Celltech. A.I. was an employee of Celltech (now UCB).(www.ikmb.uni-kiel.de).

PII: S0016-5085(05)01352-1

doi: 10.1053/j.gastro.2005.06.064

Gastroenterology
Volume 129, Issue 3 , Pages 807-818 , September 2005

Article Tools

* Image Usage & Resolution